These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3764307)

  • 21. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.
    Creager MA; Pariser KM; Winston EM; Rasmussen HM; Miller KB; Coffman JD
    Am Heart J; 1984 Aug; 108(2):370-3. PubMed ID: 6380254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.
    White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT
    Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
    Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
    J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational use of calcium-channel antagonists in Raynaud's phenomenon.
    Sturgill MG; Seibold JR
    Curr Opin Rheumatol; 1998 Nov; 10(6):584-8. PubMed ID: 9812220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects.
    Wollersheim H; Thien T; van 't Laar A
    J Clin Pharmacol; 1987 Nov; 27(11):907-13. PubMed ID: 3429697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.
    Ettinger WH; Wise RA; Schaffhauser D; Wigley FM
    Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.
    Francis JL; Roath OS; Challenor VF; Waller DG
    Br J Clin Pharmacol; 1988 Jun; 25(6):751-4. PubMed ID: 3203045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Calcium antagonists and Raynaud's phenomenon].
    Hachulla E; Devulder B
    Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].
    Shcherbakov AB
    Vutr Boles; 1988; 27(6):55-8. PubMed ID: 3247706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon.
    Finch MB; Copeland S; Passmore AP; Johnston GD
    Clin Rheumatol; 1988 Sep; 7(3):359-65. PubMed ID: 3067954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raynaud's phenomenon. An update.
    Coffman JD
    Hypertension; 1991 May; 17(5):593-602. PubMed ID: 2022404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.